$8.6bn target market...

Opening paragraph on Bells update.... NEU are chasing $8.6bn market in the US alone....

For just 2 indications. Retts and FragX. These will both have Fast track and Orphan Status..

We only have 6 months to wait for proof of efficacy although , there have been unconfirmed reports on Facebook that NNZ-2566 works....

The clincher here is that these two disease are so debilitating that if efficacy is shown, even an improvement in the condition, NEU will achieve 100% market penetration...

These numbers do not include the Autism Spectrum Disorders, Traumatic Brain Injury (severe,mild) concussion, Central Nervous System Disorders(CNS)(http://www.medicinenet.com/peripheral_neuropathy/article.htm)

BELLS put a price target on NEU of 17cents because thats how the Analysts Game works...The more often they reach their price target the better they look....It is not in their best interests to put a high figure on NEU...

So what price should we put on NEU ?. Depends on the value of NEU if the first Phase 2 is successful.... And the risk weight backwards....